Letter

Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten

BMJ 2004; 329 doi: 10.1136/bmj.329.7478.1342 (Published 2 December 2004)
Cite this as: BMJ 2004;329:1342.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Godfrey Oakley Jr (gpoakley@mindspring.com), research professor of epidemiology
  1. Rollins School of Public Health of Emory University Rollins School of Public Health, 1518 Clifton Rd, NE, Atlanta, GA 30322

    EDITOR—In their editorial Dieppe et al describe the lessons from the withdrawal of rofecoxib.1

    Randomised controlled trials are not the usual way in which serious, uncommon adverse effects of a new drug are discovered. They are usually discovered in observational studies, often case-control studies. Using randomised controlled trials to find adverse effects is dangerous. It would feed on the current vogue from trialists that the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular